



Appendix 2 – Short Form Disclosure

**Information for Vermont Prescribers of Prescription Drugs
(Short Form)**

**LIVTENCITY™
(Maribavir)**

- This list does not imply that the products on this chart are interchangeable or have the same efficacy or safety. Please refer to each product’s FDA-approved label and indication for further information.
- The prices listed below are Average Wholesale Prices (“AWP”) as established and made available to the public by a third party publisher. The price paid by consumers may be higher or lower than the prices listed below. Information about AWP of these drugs is being provided to Vermont prescribers pursuant to Vermont Law, to give you information about the relative prices of marketed drugs and other drugs in the same therapeutic class.
- The prices listed here do not necessarily reflect price per dosage, price per course of treatment or the cost effectiveness, of all the products listed. For simplicity, only the smallest package sizes available for each product are included.

Price Comparison: Marketed product and lowest dosage of other products in same therapeutic class*

MARKETED PRODUCTS:	Unit Price
Livtencity Oral Tablet 200 MG	\$ 266.78
OTHER PRODUCTS:	Unit Price
Favipiravir Oral Tablet 200 MG	\$ 0.01
Xofluza (40 MG Dose) Oral Tablet Therapy Pack 1 x 40 MG	\$ 185.40
Prevymis Oral Tablet 240 MG	\$ 270.88

*Prices shown are the lowest dosage of each product. Prices for multi-source products have been averaged. Multiple forms of the same product (e.g. tabs and caps) have been considered one product, and the prices have been averaged. Chewable forms of the product are not included. Therapeutic classes are listed in the 2004 American Hospital Formulary Service Pharmacologic-Therapeutic Classification published by the American Society of Health System Pharmacists (available at <http://www.ashp.org/ahfs>).

Additional price comparison information is available at: <https://www.takeda.com/en-us/corporate-responsibility/ethics-and-compliance/>